March 21st 2023
Sandoz will now launch both high-concentration and low-concentration versions of Hyrimoz (adalimumab-adaz) in July.
February 15th 2023
January 29th 2023
December 30th 2022
December 13th 2022
No Need for Biosimilar-to-Biosimilar Switching Studies, Authors ConcludeOctober 20th 2022
The question of whether it is safe to switch among biosimilars, not just between biosimilars and the reference product, is coming more pertinent as the number of biosimilars on the market increases.
Investigators Report High Similarity Between NovoLog and Biosimilar CandidateOctober 20th 2022
A phase 3 trial sponsored by the biosimilar maker shows that its candidate, temporarily named MYL-1601D, has the same immunogenicity, efficacy and safety levels as NovoLog, Novo Nordisk’s brand-name insulin aspart. Novolog and its authorized generic currently have the U.S. insulin aspart market to themselves.
Biosimilar Discontinuation Rates Are High But Comparable to Those for Reference Biologics: ReviewSeptember 14th 2022
The review focused on Remicade (infliximab) and Enbrel (etanercept). The annualized discontinuation rate was 21% among patients who had undergone nonmedical switching to biosimilars. However, the rates were similar to those found in some separate analyses of patients on reference biologics.
The Holy Grail Search for Affordable Insulin: The Quest ContinuesAugust 18th 2022
The Inflation Reduction Act puts a $35 cap on monthly out-of-pocket expenses for insulin. The catch: It applies only to people covered by Medicare. Some states, including California, and Civica Rx, the generic drugmaker, are gearing up to make biosimilar versions of brand-name insulin products. The competition could drive down prices.
Biosimilars Can Help Lower Patient Drug Costs When the Right Teams Come Together: Prime Therapeutics ExecutiveMay 29th 2022
Pharmacy benefit managers can help health plans understand when to best leverage and align to biosimilars and other cost-effective treatments, argues Prime Therapeutics' Kelly McGrail-Pokuta.
“Patent Thickets” on Biologics and What Could Be Done To Chop Them Down to SizeMay 10th 2022
Multiple patents on original biologics delay when biosimilars get on the market in the US. University of Denver Sturm College of Law legal experts argue in a preprint that changes in how the original patents are written could reduce the number of duplicative patents and legal gamesmanship.
Will Cyltezo Be Accepted As Interchangeabe With Humira? Researchers Sow Some Doubt.May 10th 2022
A Cleveland Clinic researcher anticipates that the FDA’s definition of strength of formulation could impair acceptance of Boehringer Ingelheim’s biosimilar to Humira (adalimumab), even though the FDA has approved the biosimilar as “interchangeable” to Humira.
Biosimilars Made a Significant Dent on 2021 Drug SpendingMay 9th 2022
Although spending on prescription drugs marched higher in 2021, the spending might have been significantly higher were it not for the savings from biosimilars, which appear to be gaining traction, according to a new report.
Humira Biosimilars Are Hitting the Market in 2023. Finally. But Will Prescriptions Follow?April 7th 2022
Marcus Snow, MD, , chair of the American College of Rheumatology’s Committee on Rheumatologic Care, discusses how additional clinical data and interchangeability designations could help build momentum for use of Humira (adalimumab) biosimilars when they start to arrive in 2023.
Biosimilars Are Supposed to Save Money. Providence St. Joseph Health Has Made That Happen.April 6th 2022
Using an aggressive utilization management approach, Providence St. Joseph Health directed physicians toward the use of biosimilars immediately after they came to market, saving nearly $27 million over two years in the process, according to Sophia Z. Humphreys, Pharm.D., M.H.A., the healthcare system’s director of system pharmacy clinical Services.
Study: Biosimilar of Rituxan Safe in ChildrenMarch 13th 2022
A large prospective study of the use of Rituxan (rituximab) and a biosimilar, Novex, has yielded safety data validating the use of this agent in pediatric patients with a wide range of diseases and conditions, ranging from oncologic and hematologic to neurologic.
Biosimilars to AMD Drugs: The Obstacles In Their WayMarch 4th 2022
Off-label Avastin, Eylea and Lucentis are the primary treatments for neovascular age-related macular degeneration (AMD), a leading cause of blindness. A recent review article looked at the impediments to the biosimilars for these drugs Ophthalmologists are wary about using biosimilars to Avastin (which was approved as a cancer drug) for AMD. Biosimilars to Eylea and Lucentis are not on the market yet. Manufacturers’ rebates and Medicare Part B “buy and bill” policies could make it difficult for them to compete against their brand-name “originator” products.
Viatris is Getting Out of Biosimilars Business… But Not CompletelyMarch 3rd 2022
The company announced this week that it is selling its biologics unit to Biocon Biologics, but Viatris is also slated to have a stake in the biosimilars entity that will bring together Biocon Biologic’s biosimilar operations and those that Viatris is selling off.
Study: Here’s Some Evidence That Switching Among Generic Levothyroxine Products Is OKMarch 1st 2022
Guidelines tell prescribers and patients to avoid switching among levothyroxine products from different manufacturers. But Mayo Clinc-led research finds little difference between switchers and nonswitchers.
Top 4 Biosimilar Developments of 2021December 10th 2021
2021 was an outstanding year for biosimilar medications, as they increased market share and adoption by healthcare providers and the first biosimilar and interchangeable insulin was approved by the FDA. Take a look at Managed Healthcare Executive's top four biosimilar developments of 2021.